Devonian Health Group is trading 14.1% up at CA$8.00 today, following a significant company announcement. - The surge comes after Health Canada authorized the Company's Clinical Trial Application to initiate a Phase II/III clinical study of Thykamine™ for mild-to-moderate atopic dermatitis in pediatric patients. - This regulatory milestone follows a roughly 30% decline in the stock price last week.